Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Penning

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonistsThomas D Penning, Mark A Russell, Barbara B Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Journal of Medicinal Chemistry|November 6, 2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agentsYunsong Tong, Jennifer J Bouska, Paul A Ellis, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolaseThomas D Penning, Nizal S Chandrakumar, Bipin N Desai, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 InhibitorsYunsong Tong, Alan S Florjancic, Rick F Clark, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolaseThomas D Penning, Nizal S Chandrakumar, Bipin N Desai, et al.
Journal of Medicinal Chemistry|July 26, 2002
Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acidThomas D Penning, Mark A Russell, Barbara B Chen, et al.
Anticancer Research|November 28, 2008
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoJoann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2005
Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic propertiesJohn A Wendt, Hongwei Wu, Heather G Stenmark, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonistsThomas D Penning, Mark A Russell, Barbara B Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Journal of Medicinal Chemistry|November 6, 2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agentsYunsong Tong, Jennifer J Bouska, Paul A Ellis, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolaseThomas D Penning, Nizal S Chandrakumar, Bipin N Desai, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 InhibitorsYunsong Tong, Alan S Florjancic, Rick F Clark, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolaseThomas D Penning, Nizal S Chandrakumar, Bipin N Desai, et al.
Journal of Medicinal Chemistry|July 26, 2002
Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acidThomas D Penning, Mark A Russell, Barbara B Chen, et al.
Anticancer Research|November 28, 2008
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoJoann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2005
Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic propertiesJohn A Wendt, Hongwei Wu, Heather G Stenmark, et al.
Pageof 5